drugset / Trial / NCT05679401
A Study With Imlifidase in Anti-GBM Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Timeline
- Start
- 2022-12-22
- Primary completion
- 2025-06-23
- Completion
- 2026-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imlifidase | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |